Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679029 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00679029 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 15 participants.
The verdict
NCT00679029, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works in treating women with HER2/neu-negative stage II or stage III breast cancer
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL bevacizumab
- DRUG doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-05-02 |
| Est. Completion | 2010-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679029
The ClinicalTrials.gov registry entry for NCT00679029 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00679029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679029 about?
NCT00679029 is a clinical study titled "Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, ...
What is the current status of trial NCT00679029?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-05-02. Estimated completion is 2010-11-18.
What interventions are being tested in trial NCT00679029?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), bevacizumab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00679029?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.